Epidemiological studies have shown that women who use third‐generation oral
contraceptives (OC) containing desogestrel, gestodene or norgestimate have a higher risk of …

Activated protein C (APC) resistance, determined with a thrombin‐generation‐based APC
resistance test, may explain risk differences of venous thrombosis in users of second‐and …

Background We have reported previously that, compared with use of second-generation oral
contraceptives, the use of third-generation oral contraceptives is associated with increased …

Resistance to activated protein C (APC) is often associated with a mutation in factor V (factor
VLeiden). Individuals without factor VLeiden who exhibit a response in functional APC …

Oral contraceptive (OC) use is associated with an increased risk of venous
thromboembolism. Previous data reported higher thrombotic risk in women using third …

Resistance to activated protein C (APC) is at present considered the most frequent
laboratory abnormality in patients with deep‐vein thrombosis. An increased risk for venous …

Recent studies suggest that low‐dose oral contraceptives may cause acquired resistance to
activated protein C (APC). The aims of this study were to determine whether hormone …

A plausible mechanism to explain thrombotic risk differences associated with the use of
second-and third-generation oral contraceptives (OCs), particularly in carriers of factor …

We investigated whether the occurrence of venous thrombosis in young women who use
oral contraceptives might be explained by the factor V Leiden mutation, which leads to …

Four epidemiologic studies showed a twofold increase in risk of deep venous thrombosis
with the use of oral contraceptives containing third-generation progestins, relative to second …